Abstract
Objectives To evaluate the clinical significance of α-FR expression in serum of patients with renal cell carcinoma and bladder cancer. Methods 58 cases of renal cell carcinoma and 42 cases of bladder cancer in our hospital were selected, 40 volunteers in the same period were selected as the control group, the differences of theα-FR expression in the serum of the three groups were compared.The expression levels ofα-FR in serum between different pathological parameters in patients with renal cell carcinoma and bladder cancer were compared. Results Theα-FR expression levels in serum of patients with renal cell carcinoma(87.39±47.15) pg/mL and patients with bladder cancer (84.52±45.68) pg/mL were higher than those of the normal control group(1.45±0.73) pg/mL, and the difference had statistical significance(P 0.05). α-FR expression level of renal cell carcinoma TNM stage I and II (67.39±39.63) pg/mL was lower than TNM stage III and VI (125.32±68.22)pg/mL, α-FR expression of renal cell carcinoma with high differentiation in serum (155.29±75.31)pg/mL was higher than that in low differentiated patients (78.85±42.68)pg/mL.α-FR expression level of bladder cancer TNM stage I and II of (84.71±53.64)pg/mL was lower than TNM stage III and VI (157.92±88.34)pg/mL, α-FR ex-pression of bladder cancer with high differentiation in serum (145.31±65.87)pg/mL was higher than that in low differentiated patients (79.64±48.22)pg/mL. Conclusions The expression level of α-FR in serum can be used as a tumor marker for diagnosis of renal cell carcinoma and bladder cancer. Key words: Urinary Bladder Neoplasms; Kidney Neoplasms; Folic Acid; Receptors
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call